-
Your selected country is
eu
- Change country/language
Old Browser
Your account has been put on hold due to inactivity. To re-activate, check your account information and make all necessary updates.
Looks like you're visiting us from {{countryName}}.
Would you like to remain on the current country site or be redirected to one based on your location?
live copy GB
Your account has been put on hold due to inactivity. To re-activate, check your account information and make all necessary updates.
Bifidobacteria-Mediated Immune System Imprinting Early In Life
There is mounting evidence to suggest that during the first 3 months of life, the infant gut microbiome is crucial for immune development. Specialised microbes in the infant gut that rely on breast milk for nutrients play a key role in immune-microbe interactions.1 Such interactions can influence the risk of allergies, asthma and other inflammatory disorders. Human breastmilk contains abundant human milk oligosaccharides (HMOs) which cannot be digested by humans. Evolution has provided selective advantages to beneficial microbes like Bifidobacterium longum by giving them the ability to metabolise HMOs.1
In this article published by the group of Petter Brodin at the Karolinska University Hospital, Sweden, the authors have aimed to demonstrate that the lack of bifidobacteria, and in particular, the depletion of genes necessary for HMO utilisation from the metagenome, is associated with systemic inflammation and immune dysregulation in early life.
The authors have used blood immune cell profiling by mass cytometry, immune plasma profiling and fecal metabolomics, T cell polarisation experiments, including targeted transcriptome and protein profiling by BD RhapsodyTM Single Cell Analysis System, and fecal cytokine measurements in the study.
The authors propose that there is a transient immune response to colonising microbes during the first few weeks of life. The colonisation of the gut microbiome is by itself, an important determinant of this immune response. Bacteria expressing HMO-utilisation genes influence the immune-microbe interactions by reducing inflammatory responses. In breastfed infants who were given Bifidobacterium infansis EVC001, a bacterium that expresses HMO-utilisation genes, the authors noticed the silencing of intestinal T cell helper 2 (Th2) and Th17 cytokines, along with an induction of interferon β (Infβ). HMO metabolites like indolelactate and indole-3-lactic acid (ILA), found in abundance in the fecal water of EVC001-fed infants, were found by the authors to upregulate (in vitro) the immunoregulatory galectin-1, which is known to limit T cell activation in Th2 and Th17 cells.
The authors propose that an immunological sequence of events that are triggered by microbial colonisation results either in a balanced immune-microbe relationship or varying degrees of intestinal and systemic inflammation and perturbed T cell regulation. They also propose that their results highlight the importance of early microbial colonisation during a key window of immunological development, where opportunities exist for supplementing the gut microbiome with potential benefits for the infant. 2
Read the Cell article “Bifidobacteria-mediated immune system imprinting early in life”
1 Sela, D.A., Chapman, J., Adeuya, A., et al. (2008). The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc. Natl. Acad. Sci. USA 105, 18964–18969.
2 Henrick et al., Bifidobacteria-mediated immune system imprinting early in life, Cell (2021), https://doi.org/
10.1016/j.cell.2021.05.030
This list of references to third-party peer-reviewed material and the sites they are hosted on are provided for your reference and convenience only and do not imply any review or endorsement of the material or any association with their operators. The Third-Party References (and the Web sites to which they link) may contain information that is inaccurate, incomplete, or outdated. Your access and use of the Third Party Sites (and any Web sites to which they link) is solely at your own risk.
BD, the BD Logo and Rhapsody are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners © 2021 BD. All rights reserved.
Products are for Research Use Only. Not for use in diagnostic or therapeutic procedures.
Report a Site Issue
This form is intended to help us improve our website experience. For other support, please visit our Contact Us page.